Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Watada H;Watada H; Imori M; Imori M; Li P; Li P; Iwamoto N; Iwamoto N
- Source:
Endocrine journal [Endocr J] 2017 Jul 28; Vol. 64 (7), pp. 705-717. Date of Electronic Publication: 2017 May 24.
- Publication Type:
Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
- Language:
English
- Additional Information
- Source:
Publisher: Japan Endocrine Society Country of Publication: Japan NLM ID: 9313485 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1348-4540 (Electronic) Linking ISSN: 09188959 NLM ISO Abbreviation: Endocr J Subsets: MEDLINE
- Publication Information:
Original Publication: Tokyo : Japan Endocrine Society, [1993-
- Subject Terms:
- Abstract:
In Japan, premixed insulins are commonly used as starter insulin for type 2 diabetes. This subpopulation analysis assessed the efficacy and safety of twice-daily LM25 (25% insulin lispro/75% insulin lispro protamine) and LM50 (50% insulin lispro/50% insulin lispro protamine) as starter insulin in Japanese subjects, and compared these results with the whole-trial populations of East Asian subjects. In this subpopulation analysis of an open-label, phase 4, randomized trial (CLASSIFY), Japanese subjects received LM25 (n = 88) or LM50 (n = 84) twice-daily for 26 weeks. The primary outcome was change from baseline at Week 26 in glycated hemoglobin (HbA1c). Results for Japanese subjects were generally similar to those for the whole-trial population. Similar changes from baseline in HbA1c were observed for LM25 and LM50 groups (least squares [LS] mean difference [95% confidence interval] of LM25 - LM50 = 0.13 [-0.16, 0.41]%, 1.42 [-1.75, 4.48] mmol/mol, p = 0.388). More LM50-treated subjects than LM25-treated subjects achieved HbA1c targets of <7.0% (59.5% versus 43.2%; p = 0.034) or ≤6.5% (45.2% versus 28.4%; p = 0.027). The reduction in postprandial blood glucose concentrations after morning and evening meals was statistically significantly greater for LM50 than for LM25. The incidence of both hypoglycemia and treatment-emergent adverse events were similar between treatment groups. Both LM25 and LM50 twice daily appear to be effective and well tolerated as starter insulin, although LM50 might be more effective for Japanese type 2 diabetes patients.
- Contributed Indexing:
Keywords: Insulin lispro; Japan; Premixed insulin
- Accession Number:
0 (Biphasic Insulins)
0 (Blood Glucose)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
0 (Insulin Lispro)
0 (hemoglobin A1c protein, human)
0 (insulin lispro, isophane insulin lispro drug combination (25:75))
0 (isophane insulin, insulin lispro drug combination 50:50)
53027-39-7 (Insulin, Isophane)
- Publication Date:
Date Created: 20170526 Date Completed: 20180430 Latest Revision: 20221207
- Publication Date:
20240829
- Accession Number:
10.1507/endocrj.EJ17-0020
- Accession Number:
28539526
No Comments.